

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 27, 2025**

---

**UNIVERSAL HEALTH REALTY INCOME TRUST**

(Exact name of Registrant as Specified in Its Charter)

---

**Maryland**  
(State or Other Jurisdiction  
of Incorporation)

**1-9321**  
(Commission File Number)

**23-6858580**  
(IRS Employer  
Identification No.)

**Universal Corporate Center  
367 South Gulph Road  
King of Prussia, Pennsylvania**  
(Address of Principal Executive Offices)

**19406**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: (610) 265-0688**

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Shares of beneficial interest, \$0.01 par value	UHT	New York Stock Exchange

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 2.02 Results of Operations and Financial Condition.**

On October 27, 2025, the Trust made its third quarter, 2025 earnings release. A copy of the Trust's press release is furnished as exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit Number</u>	<u>Description</u>
99.1	<a href="#">Press release dated October 27, 2025.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

## Exhibit Index

Exhibit Number	Description
99.1	<a href="#">Press release dated October 27, 2025.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

UNIVERSAL HEALTH REALTY INCOME TRUST

Date: October 27, 2025

By: /s/ Charles F. Boyle

Name: Charles F. Boyle

Title: Senior Vice President and Chief Financial Officer

---

**UNIVERSAL HEALTH REALTY INCOME TRUST**

Universal Corporate Center  
367 S. Gulph Road  
P.O. Box 61558  
King of Prussia, PA 19406  
(610) 265-0688

**FOR IMMEDIATE RELEASE**

**CONTACT: Charles Boyle**  
**Chief Financial Officer**  
**(610) 768-3300**

**October 27, 2025**

**UNIVERSAL HEALTH REALTY INCOME TRUST**  
**REPORTS FINANCIAL RESULTS FOR THE THREE AND NINE-MONTH**  
**PERIODS ENDED SEPTEMBER 30, 2025**

*Consolidated Results of Operations - Three-Month Periods Ended September 30, 2025 and 2024:*

KING OF PRUSSIA, PA - Universal Health Realty Income Trust (NYSE:UHT) announced today that for the three-month period ended September 30, 2025, net income was \$4.0 million, or \$.29 per diluted share, as compared to \$4.0 million, or \$.29 per diluted share, during the third quarter of 2024.

Our net income during the third quarter of 2025, as compared to third quarter of 2024, included the following: (i) an increase of \$275,000, or \$.02 per diluted share, resulting from a one-time settlement and release agreement executed during the third quarter of 2025 in connection with one of our medical office buildings, and; (ii) an other combined net decrease of \$256,000, or \$.02 per diluted share, resulting primarily from a decrease in the net aggregate income generated at various properties, including approximately \$900,000 of nonrecurring depreciation expense recorded during the third quarter of 2025.

As calculated on the attached Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule"), our funds from operations ("FFO"), which excludes depreciation and amortization expense, increased by \$908,000, or \$.06 per diluted share to \$12.2 million, or \$.88 per diluted share, during the third quarter of 2025, as compared to \$11.3 million, or \$.82 per diluted share, during the third quarter of 2024.

*Consolidated Results of Operations - Nine-Month Periods Ended September 30, 2025 and 2024:*

For the nine-month period ended September 30, 2025, net income was \$13.3 million, or \$.96 per diluted share, as compared to \$14.6 million, or \$1.05 per diluted share, during the comparable period of 2024.

The decrease in our net income of \$1.3 million, or \$.09 per diluted share, during the first nine months of 2025, as compared to the comparable period of 2024, consisted of the following: (i) a decrease of \$730,000, or \$.05 per diluted share, resulting from an aggregate net decrease in the income generated at various properties, including the above-mentioned nonrecurring depreciation expense of approximately \$900,000 recorded during the third quarter of 2025; (ii) a decrease of \$563,000, or \$.04 per diluted share, related to a property tax reduction recorded during the first nine months of 2024 at our property located in Chicago, Illinois, (iii) an increase of \$275,000, or \$.02 per diluted share, resulting from the above-mentioned, one-time settlement and release agreement executed during the third quarter of 2025, and; (iv) a decrease of \$282,000, or \$.02 per diluted share, resulting from an increase in interest

---

expense due primarily to an increase in our average borrowings outstanding pursuant to our credit agreement.

As calculated on the attached Supplemental Schedule, our FFO, which excludes depreciation and amortization expense, decreased by \$166,000, or \$.02 per diluted share, to \$35.9 million, or \$2.59 per diluted share, during the first nine months of 2025, as compared to \$36.1 million, or \$2.61 per diluted share during the comparable period of 2024.

*Dividend Information:*

The third quarter dividend of \$.74 per share, or \$10.3 million in the aggregate, was declared on September 22, 2025 and paid on September 30, 2025.

*Capital Resources Information:*

As of September 30, 2025, pursuant the terms of our \$425 million credit agreement which is scheduled to expire on September 30, 2028, we had \$67.9 million of available borrowing capacity, net of \$357.1 million of borrowings. We have the option to extend the credit agreement for up to two additional six-month periods.

*Palm Beach Gardens Medical Plaza I:*

In October 2025, we entered into a ground lease with a wholly-owned subsidiary of UHS with the intent to develop, construct and own the real property of Palm Beach Gardens Medical Plaza I, an 80,000 square foot medical office building ("MOB") located in Palm Beach Gardens, Florida. This MOB will be located on the campus of the Alan B. Miller Medical Center, a newly constructed acute care hospital owned and operated by a wholly-owned subsidiary of UHS, which is scheduled to be completed and opened during the third quarter of 2026.

Construction of this MOB, for which we have engaged a wholly-owned subsidiary of UHS to act as project manager, is expected to commence in November, 2025. The cost of the MOB is estimated to be approximately \$34 million. A wholly-owned subsidiary of UHS has executed a 10-year master flex lease agreement, which is subject to reduction based on the execution of third-party leases, for approximately 75% of the rentable square feet of the MOB.

*General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:*

Universal Health Realty Income Trust, a real estate investment trust, invests in healthcare and human-service related facilities including acute care hospitals, behavioral health care hospitals, specialty facilities, medical/office buildings, free-standing emergency departments and childcare centers. We have investments or commitments in seventy-seven properties located in twenty-one states.

This press release contains forward-looking statements based on current management expectations. Numerous factors, including those disclosed herein, as well as the operations and financial results of each of our tenants, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in *Item 1A-Risk Factors* and in *Item 7 - Forward-Looking Statements* in our Form 10-K for the year ended December 31, 2024 and in *Item 2 - Forward-Looking Statements and Certain Risk Factors* in our Form 10-Q for the quarter ended June 30, 2025), may cause the results to differ materially from those anticipated in the forward-looking statements. Readers should not place undue reliance on such forward-looking statements which reflect management's view only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

---

Many of the factors that could affect our future results are beyond our control or ability to predict. Future operations and financial results of our tenants, and in turn ours, could be materially impacted by various developments including, but not limited to, potential significant reductions in federal funding for state Medicaid programs, and/or other potential changes, which would likely result in reduced Medicaid payments to the operators of our facilities; decreases in staffing availability and related increases to wage expense experienced by our tenants resulting from the shortage of nurses and other clinical staff and support personnel; the impact of government and administrative regulation of the health care industry; declining patient volumes and unfavorable changes in payer mix caused by deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients as the result of business closings and layoffs); potential cost increases and disruptions related to supplies and building materials resulting from changes in laws or policies governing the terms of foreign trade, and in particular, increased trade restrictions, tariffs or taxes on imports from where the products or materials are made; and potential increases to other expenditures.

In addition, the increase in interest rates during the past few years has substantially increased our borrowings costs and reduced our ability to access the capital markets on favorable terms. Additional increases in interest rates could have a significant unfavorable impact on our future results of operations and the resulting effect on the capital markets could adversely affect our ability to carry out our strategy.

We believe that, if and when applicable, adjusted net income and adjusted net income per diluted share (as reflected on the Supplemental Schedule), which are non-GAAP financial measures (“GAAP” is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect in each year of material items that are non-recurring or non-operational in nature including items such as, but not limited to, gains or losses on transactions.

Funds from operations (“FFO”) is a widely recognized measure of performance for Real Estate Investment Trusts (“REITs”). We believe that FFO and FFO per diluted share, which are non-GAAP financial measures, are helpful to our investors as measures of our operating performance. We compute FFO, as reflected on the attached Supplemental Schedules, in accordance with standards established by the National Association of Real Estate Investment Trusts (“NAREIT”), which may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, or that interpret the NAREIT definition differently than we interpret the definition. FFO adjusts for the effects of certain items, such as gains or losses on transactions that occurred during the periods presented. FFO does not represent cash generated from operating activities in accordance with GAAP and should not be considered to be an alternative to net income determined in accordance with GAAP. In addition, FFO should not be used as: (i) an indication of our financial performance determined in accordance with GAAP; (ii) an alternative to cash flow from operating activities determined in accordance with GAAP; (iii) a measure of our liquidity, or; (iv) an indicator of funds available for our cash needs, including our ability to make cash distributions to shareholders. A reconciliation of our reported net income to FFO is reflected on the Supplemental Schedules included below.

To obtain a complete understanding of our financial performance these measures should be examined in connection with net income, determined in accordance with GAAP, as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-K for the year ended December 31, 2024 and our Report on Form 10-Q for the quarter ended June 30, 2025. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented,

---

are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.

(more)

---

**Universal Health Realty Income Trust**  
Consolidated Statements of Income  
For the Three and Nine Months Ended September 30, 2025 and 2024  
(amounts in thousands, except share information)  
(unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
<b>Revenues:</b>				
Lease revenue - UHS facilities (a.)	\$ 8,367	\$ 8,248	\$ 25,075	\$ 25,366
Lease revenue - Non-related parties	14,777	14,342	43,676	43,188
Other revenue - UHS facilities	233	242	699	682
Other revenue - Non-related parties	577	305	1,218	1,056
Interest income on financing leases - UHS facilities	1,348	1,357	4,050	4,077
	<u>25,302</u>	<u>24,494</u>	<u>74,718</u>	<u>74,369</u>
<b>Expenses:</b>				
Depreciation and amortization	7,903	7,009	21,742	20,624
Advisory fees to UHS	1,414	1,386	4,169	4,093
Other operating expenses	7,591	7,609	22,535	22,115
	<u>16,908</u>	<u>16,004</u>	<u>48,446</u>	<u>46,832</u>
Income before equity in income of unconsolidated limited liability companies ("LLCs") and interest expense	8,394	8,490	26,272	27,537
Equity in income of unconsolidated LLCs	438	300	1,215	956
Interest expense, net	(4,816)	(4,793)	(14,202)	(13,920)
Net income	<u>\$ 4,016</u>	<u>\$ 3,997</u>	<u>\$ 13,285</u>	<u>\$ 14,573</u>
Basic earnings per share	<u>\$ 0.29</u>	<u>\$ 0.29</u>	<u>\$ 0.96</u>	<u>\$ 1.06</u>
Diluted earnings per share	<u>\$ 0.29</u>	<u>\$ 0.29</u>	<u>\$ 0.96</u>	<u>\$ 1.05</u>
Weighted average number of shares outstanding - Basic	<u>13,828</u>	<u>13,807</u>	<u>13,818</u>	<u>13,799</u>
Weighted average number of shares outstanding - Diluted	<u>13,874</u>	<u>13,849</u>	<u>13,860</u>	<u>13,835</u>

(a.) Includes bonus rental on McAllen Medical Center, a UHS acute care hospital facility, of \$895 and \$765 for the three-month periods ended September 30, 2025 and 2024, respectively, and \$2.6 million and \$2.3 million for the nine-month periods ended September 30, 2025 and 2024, respectively.

**Universal Health Realty Income Trust**  
Schedule of Non-GAAP Supplemental Information (“Supplemental Schedule”)  
For the Three Months Ended September 30, 2025 and 2024  
(amounts in thousands, except share information)  
(unaudited)

**Calculation of Funds From Operations (“FFO”)**

	<u>Three Months Ended September 30, 2025</u>		<u>Three Months Ended September 30, 2024</u>	
	<u>Amount</u>	<u>Per Diluted Share</u>	<u>Amount</u>	<u>Per Diluted Share</u>
Net income	\$ 4,016	\$ 0.29	\$ 3,997	\$ 0.29
Plus: Depreciation and amortization expense:				
Consolidated investments	7,903	0.57	7,009	0.51
Unconsolidated affiliates	306	0.02	311	0.02
FFO	<u>\$ 12,225</u>	<u>\$ 0.88</u>	<u>\$ 11,317</u>	<u>\$ 0.82</u>
Dividend paid per share		<u>\$ 0.740</u>		<u>\$ 0.730</u>

**Universal Health Realty Income Trust**  
Schedule of Non-GAAP Supplemental Information (“Supplemental Schedule”)  
For the Nine Months Ended September 30, 2025 and 2024  
(amounts in thousands, except share information)  
(unaudited)

**Calculation of Funds From Operations (“FFO”)**

	<u>Nine Months Ended September 30, 2025</u>		<u>Nine Months Ended September 30, 2024</u>	
	<u>Amount</u>	<u>Per Diluted Share</u>	<u>Amount</u>	<u>Per Diluted Share</u>
Net income	\$ 13,285	\$ 0.96	\$ 14,573	\$ 1.05
Plus: Depreciation and amortization expense:				
Consolidated investments	21,742	1.57	20,624	1.49
Unconsolidated affiliates	922	0.06	918	0.07
FFO	<u>\$ 35,949</u>	<u>\$ 2.59</u>	<u>\$ 36,115</u>	<u>\$ 2.61</u>
Dividend paid per share		<u>\$ 2.215</u>		<u>\$ 2.185</u>

**Universal Health Realty Income Trust**  
Consolidated Balance Sheets  
(amounts in thousands, except share information)  
(unaudited)

	September 30, 2025	December 31, 2024
<b>Assets:</b>		
<b>Real Estate Investments:</b>		
Buildings and improvements and construction in progress	\$ 661,258	\$ 655,996
Accumulated depreciation	(306,553)	(286,932)
	354,705	369,064
Land	56,870	56,870
Net Real Estate Investments	411,575	425,934
Financing receivable from UHS	82,315	82,798
Net Real Estate Investments and Financing receivable	493,890	508,732
Investments in limited liability companies ("LLCs")	20,817	13,948
<b>Other Assets:</b>		
Cash and cash equivalents	6,916	7,097
Lease and other receivables from UHS	6,985	7,131
Lease receivable - other	8,720	7,975
Intangible assets (net of accumulated amortization of \$11.3 million during each period)	6,045	7,325
Right-of-use land assets, net	10,896	10,918
Deferred charges, notes receivable and other assets, net	13,768	17,736
Total Assets	\$ 568,037	\$ 580,862
<b>Liabilities:</b>		
Line of credit borrowings	\$ 357,050	\$ 348,900
Mortgage notes payable, non-recourse to us, net	18,575	19,349
Accrued interest	885	694
Accrued expenses and other liabilities	11,230	10,444
Ground lease liabilities, net	10,896	10,918
Tenant reserves, deposits and deferred and prepaid rents	10,827	11,016
Total Liabilities	409,463	401,321
<b>Equity:</b>		
Preferred shares of beneficial interest, \$.01 par value; 5,000,000 shares authorized; none issued and outstanding	-	-
Common shares, \$.01 par value; 95,000,000 shares authorized; issued and outstanding: 2025 - 13,873,583; 2024 - 13,849,424	139	138
Capital in excess of par value	271,833	271,092
Cumulative net income	858,580	845,295
Cumulative dividends	(974,107)	(943,396)
Accumulated other comprehensive income	2,129	6,412
Total Equity	158,574	179,541
Total Liabilities and Equity	\$ 568,037	\$ 580,862

